

Michael Maeng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4459634/publications.pdf>

Version: 2024-02-01

245
papers

13,120
citations

47409

49
h-index

28425

109
g-index

285
all docs

285
docs citations

285
times ranked

11576
citing authors

#	ARTICLE	IF	CITATIONS
1	Design and Rationale of a Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE). <i>Cardiovascular Revascularization Medicine</i> , 2022, 34, 17-24.	0.3	9
2	Thirteen-year trends in cardiovascular risk in men and women with chronic coronary syndrome. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 437-446.	1.8	3
3	Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 434-441.	1.4	1
4	Cardiovascular risks associated with smoking in patients without obstructive coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e14-e17.	0.8	0
5	Early vascular healing after implantation of the polymer-free biolimus-eluting stent or the ultrathin strut biodegradable polymer sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction. <i>Coronary Artery Disease</i> , 2022, Publish Ahead of Print, .	0.3	0
6	Development and validation of an artificial neural network algorithm to predict mortality and admission to hospital for heart failure after myocardial infarction: a nationwide population-based study. <i>The Lancet Digital Health</i> , 2022, 4, e37-e45.	5.9	16
7	Impact of diabetes on 1-year clinical outcome in patients undergoing revascularization with the BioFreedom stents or the Orsiro stents from the SORT OUT IX trial. <i>Catheterization and Cardiovascular Interventions</i> , 2022, , .	0.7	0
8	Effectiveness and Safety of Ticagrelor Implementation in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: A Cohort Study in Western Denmark. <i>Lancet Regional Health - Europe</i> , The, 2022, 14, 100301.	3.0	6
9	Association of Coronary Plaque With Low-Density Lipoprotein Cholesterol Levels and Rates of Cardiovascular Disease Events Among Symptomatic Adults. <i>JAMA Network Open</i> , 2022, 5, e2148139.	2.8	21
10	Comparison of MynxGrip vascular closure device and manual compression for closure after femoral access angiography: a randomized controlled trial: the closure devices used in every day practice study, CLOSE-UP III trial. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 68.	0.7	9
11	5-Year Outcomes of PCI Guided by Measurement of Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve. <i>Journal of the American College of Cardiology</i> , 2022, 79, 965-974.	1.2	30
12	Clinical outcomes of everolimus-eluting bioresorbable scaffolds or everolimus-eluting stents in patients with acute myocardial infarction: two-year results of the randomised ISAR-Absorb MI trial. <i>EuroIntervention</i> , 2022, 17, 1348-1351.	1.4	3
13	Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent. <i>Catheterization and Cardiovascular Interventions</i> , 2022, , .	0.7	2
14	Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score. <i>European Heart Journal</i> , 2022, 43, 996-1004.	1.0	8
15	OUP accepted manuscript. <i>European Heart Journal</i> , 2022, , .	1.0	2
16	Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2022, , .	0.4	5
17	Clinical Validation of a Virtual Planner for Coronary Interventions Based on Coronary CT Angiography. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1242-1255.	2.3	36
18	Polymer-free biolimus-coated stents versus ultrathin-strut biodegradable polymer sirolimus-eluting stents: two-year outcomes of the randomised SORT OUT IX trial. <i>EuroIntervention</i> , 2022, 18, e124-e131.	1.4	7

#	ARTICLE	IF	CITATIONS
19	Estimated Pulse Wave Velocity Is Associated With All-Cause Mortality During 8.5 Years Follow-Up in Patients Undergoing Elective Coronary Angiography. <i>Journal of the American Heart Association</i> , 2022, 11, e025173.	1.6	12
20	Microvascular disease increases the risk of lower limb amputation – A Western Danish cohort study. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13812.	1.7	4
21	Association between REDUCE-IT criteria, coronary artery disease severity, and cardiovascular events: the Western Denmark Heart Registry. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1802-1810.	0.8	4
22	Long-Term Outcomes of Perioperative Versus Nonoperative Myocardial Infarction: A Danish Population-Based Cohort Study (2000–2016). <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, .	0.9	1
23	Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population. <i>Rheumatology</i> , 2021, 60, 1400-1409.	0.9	32
24	Insulin-treated versus noninsulin-treated diabetes and risk of ischemic stroke in patients with atrial fibrillation. <i>Vascular Pharmacology</i> , 2021, 136, 106809.	1.0	5
25	SARS-CoV-2 infection and adverse outcomes in users of ACE inhibitors and angiotensin-receptor blockers: a nationwide case-control and cohort analysis. <i>Thorax</i> , 2021, 76, 370-379.	2.7	15
26	Peripheral artery disease, lower limb revascularization, and amputation in diabetes patients with and without coronary artery disease: a cohort study from the Western Denmark Heart Registry. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001803.	1.2	16
27	Instantaneous wave-free ratio guided multivessel revascularisation during percutaneous coronary intervention for acute myocardial infarction: study protocol of the randomised controlled iMODERN trial. <i>BMJ Open</i> , 2021, 11, e044035.	0.8	4
28	Rationale and design of the precise percutaneous coronary intervention plan (P3) study: Prospective evaluation of a virtual computed tomography-based percutaneous intervention planner. <i>Clinical Cardiology</i> , 2021, 44, 446-454.	0.7	14
29	Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. <i>Lancet, The</i> , 2021, 397, 985-995.	6.3	208
30	Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 768-780.	1.1	5
31	Randomized Clinical Comparison of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Combo Stent With the Sirolimus-Eluting Orsiro Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT X Trial. <i>Circulation</i> , 2021, 143, 2155-2165.	1.6	25
32	Interplay of Risk Factors and Coronary Artery Calcium for CHD Risk in Young Patients. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2387-2396.	2.3	16
33	Prognostic Value of Coronary Artery Calcium in Symptomatic Young Individuals Age 18 to 45 Years. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2980-2982.	1.2	0
34	Optical coherence tomography tissue coverage and characterization at six months after implantation of bioresorbable scaffolds versus conventional everolimus eluting stents in the ISAR-Absorb MI trial. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 2815-2826.	0.7	1
35	Nationwide Trends in Cardiac Risk and Mortality in Patients With Incident Type 2 Diabetes: A Danish Cohort Study. <i>Diabetes Care</i> , 2021, 44, 2353-2360.	4.3	14
36	Comment on: Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population: reply. <i>Rheumatology</i> , 2021, 60, e419-e420.	0.9	0

#	ARTICLE	IF	CITATIONS
37	Risk of Myocardial Infarction and Death After Noncardiac Surgery Performed Within the First Year After Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome or Stable Angina Pectoris. <i>American Journal of Cardiology</i> , 2021, 160, 14-20.	0.7	2
38	Ten-year cardiovascular risk in diabetes patients without obstructive coronary artery disease: a retrospective Western Denmark cohort study. <i>Cardiovascular Diabetology</i> , 2021, 20, 23.	2.7	6
39	CHA 2 DS 2 -VASc impact on risk following percutaneous coronary intervention in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2021, , e13717.	1.7	0
40	Cardiovascular risk in patients with and without diabetes presenting with chronic coronary syndrome in 2004-2016. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 579.	0.7	3
41	16-year follow-up of the Danish Acute Myocardial Infarction 2 (DANAMI-2) trial: primary percutaneous coronary intervention vs. fibrinolysis in ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2020, 41, 847-854.	1.0	39
42	Smoking is the dominating modifiable risk factor in younger patients with STEMI. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 70-75.	0.4	9
43	Interaction of ischaemic postconditioning and thrombectomy in patients with ST-elevation myocardial infarction. <i>Heart</i> , 2020, 106, 24-32.	1.2	11
44	Ten-Year Outcomes of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stents in Patients With Versus Without Diabetes Mellitus (SORT OUT III). <i>American Journal of Cardiology</i> , 2020, 125, 349-353.	0.7	5
45	Clinical outcomes three-year after revascularization with biodegradable polymer stents: ultrathin-strut sirolimus-eluting stent versus biolimus-eluting stent: from the Scandinavian organization for randomized trials with clinical outcome VII trial. <i>Coronary Artery Disease</i> , 2020, 31, 485-492.	0.3	9
46	Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2289-2301.	1.2	123
47	A Novel Model for Prediction of Thromboembolic and Cardiovascular Events in Patients Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2020, 131, 40-48.	0.7	7
48	Risk of Myocardial Infarction in Patients Without Angiographic Coronary Artery Disease Compared With the General Population. <i>American Journal of Cardiology</i> , 2020, 132, 8-14.	0.7	3
49	Response to -Correspondence on -Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease-by Jong et al. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrhumdis-2020-219231.	0.5	0
50	Diabetes is not a risk factor for myocardial infarction in patients without coronary artery disease: A study from the Western Denmark Heart Registry. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412094180.	0.9	5
51	Reply. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 658-659.	1.1	0
52	Agreement between nonculprit stenosis follow-up iFR and FFR after STEMI (iSTEMI substudy). <i>BMC Research Notes</i> , 2020, 13, 410.	0.6	4
53	Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1182-1188.	0.5	16
54	Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 141, 2052-2063.	1.6	48

#	ARTICLE	IF	CITATIONS
55	Instantaneous wave-free ratio cutoff values for nonculprit stenosis classification in patients with ST-segment elevation myocardial infarction (an iSTEMI substudy). <i>Coronary Artery Disease</i> , 2020, 31, 411-416.	0.3	1
56	Randomised comparison of provisional side branch stenting versus a two-stent strategy for treatment of true coronary bifurcation lesions involving a large side branch: the Nordic-Baltic Bifurcation Study IV. <i>Open Heart</i> , 2020, 7, e000947.	0.9	34
57	Evaluation and Management of Nonculprit Lesions in STEMI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1145-1154.	1.1	33
58	Renin-“Angiotensin System Blockers and Adverse Outcomes of Influenza and Pneumonia: A Danish Cohort Study. <i>Journal of the American Heart Association</i> , 2020, 9, e017297.	1.6	7
59	Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: a pooled analysis of individual patient data. <i>EuroIntervention</i> , 2020, 15, 1451-1457.	1.4	14
60	Culprit lesion morphology in patients with ST-segment elevation myocardial infarction assessed by optical coherence tomography. <i>Coronary Artery Disease</i> , 2020, 31, 671-677.	0.3	0
61	Validation of the European Society of Cardiology and European Society of Anaesthesiology non-cardiac surgery risk score in patients treated with coronary drug-eluting stent implantation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 22-27.	1.8	12
62	Everolimus-Eluting Versus Biolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2019, 124, 671-677.	0.7	6
63	TCT-290 Outcomes After Revascularization With a Polymer-Free Biolimus-Eluting BioFreedom Stent or a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Orsiro Stent in Patients With and Without Acute Coronary Syndromes: From the SORT OUT IX Trial. <i>Journal of the American College of Cardiology</i> , 2019, 74, B289.	1.2	0
64	TCT-11 Everolimus-Eluting Bioresorbable Scaffolds Versus Drug-Eluting Stents in Patients With Acute Myocardial Infarction: 2-Year Results of the Randomized ISAR-Absorb MI Trial. <i>Journal of the American College of Cardiology</i> , 2019, 74, B11.	1.2	0
65	Research update for articles published in EJCI in 2017. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13163.	1.7	0
66	Diabetes Mellitus Is Associated With Increased Risk of Ischemic Stroke in Patients With and Without Coronary Artery Disease. <i>Stroke</i> , 2019, 50, 3347-3354.	1.0	32
67	Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial. <i>Lancet, The</i> , 2019, 394, 1415-1424.	6.3	223
68	<p>Extent of coronary artery disease is associated with myocardial infarction and mortality in patients with diabetes mellitus [Response to Letter]<p>. <i>Clinical Epidemiology</i> , 2019, Volume 11, 721-722.	1.5	1
69	Comparison of Acute Versus Subacute Coronary Angiography in Patients With NON-ST-Elevation Myocardial Infarction (from the NONSTEMI Trial). <i>American Journal of Cardiology</i> , 2019, 124, 825-832.	0.7	10
70	<p>Extent of coronary artery disease is associated with myocardial infarction and mortality in patients with diabetes mellitus<p>. <i>Clinical Epidemiology</i> , 2019, Volume 11, 419-428.	1.5	13
71	Comparison of the polymer-free biolimus-coated BioFreedom stent with the thin-strut biodegradable polymer sirolimus-eluting Orsiro stent in an all-comers population treated with percutaneous coronary intervention: Rationale and design of the randomized SORT OUT IX trial. <i>American Heart Journal</i> , 2019, 213, 1-7.	1.2	10
72	Procedural findings and early healing response after implantation of a self-apposing bioresorbable scaffold in coronary bifurcation lesions. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1199-1210.	0.7	5

#	ARTICLE	IF	CITATIONS
73	Predicting stroke in patients without atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13103.	1.7	5
74	Quantitative flow ratio for immediate assessment of nonculprit lesions in patients with ST-segment elevation myocardial infarction—An iSTEMI substudy. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 686-692.	0.7	45
75	External applicability of the COMPASS trial: the Western Denmark Heart Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 192-199.	1.4	12
76	Risk stratification by assessment of coronary artery disease using coronary computed tomography angiography in diabetes and non-diabetes patients: a study from the Western Denmark Cardiac Computed Tomography Registry. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 1271-1278.	0.5	15
77	Assessing the Nationwide Impact of a Registry-Based Randomized Clinical Trial on Cardiovascular Practice. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007381.	1.4	16
78	Association between anti-diabetes treatments and cardiovascular risk in diabetes patients with and without coronary artery disease. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 351-359.	0.9	8
79	Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 624-633.	1.1	27
80	Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2346-2355.	1.1	13
81	Nurse-led Motivational Telephone Follow-up After Same-day Percutaneous Coronary Intervention Reduces Readmission and Contacts to General Practice. <i>Journal of Cardiovascular Nursing</i> , 2019, 34, 222-230.	0.6	13
82	Very late Absorb scaffold thrombosis. <i>Coronary Artery Disease</i> , 2019, 30, 232-233.	0.3	0
83	Comparison of Frequency of Ischemic Stroke in Patients With Versus Without Coronary Heart Disease and Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019, 123, 153-158.	0.7	10
84	Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial. <i>European Heart Journal</i> , 2019, 40, 167-176.	1.0	40
85	Impact of diabetes on clinical outcomes after revascularization with sirolimus-eluting and biolimus-eluting stents with biodegradable polymer from the SORT OUT VII trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 567-573.	0.7	11
86	Five-year safety and performance data of a novel third-generation novolimus-eluting bioresorbable scaffold in single de novo lesions. <i>EuroIntervention</i> , 2019, 15, 685-687.	1.4	3
87	Enhanced platelet inhibition by clopidogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation. <i>EuroIntervention</i> , 2019, 15, 700-706.	1.4	5
88	Ten-year outcomes from a randomised comparison of zotarolimus-eluting and sirolimus-eluting stents: the SORT OUT III study. <i>EuroIntervention</i> , 2019, 15, e1022-e1024.	1.4	6
89	Development of heart failure in patients with rheumatoid arthritis: A Danish population-based study. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12915.	1.7	30
90	The year in cardiology 2017: coronary interventions. <i>European Heart Journal</i> , 2018, 39, 914-924.	1.0	1

#	ARTICLE	IF	CITATIONS
91	Evaluation of Coronary Artery Stenosis by Quantitative Flow Ratio During Invasive Coronary Angiography. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007107.	1.3	157
92	The Western Denmark Heart Registry. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1259-1272.	1.2	90
93	Randomized comparison of sirolimus eluting, and biolimus eluting bioresorbable polymer stents: the SORT-OUT VII optical coherence tomography study. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 329-338.	0.5	5
94	Computed tomography derived fractional flow reserve testing in stable patients with typical angina pectoris: influence on downstream rate of invasive coronary angiography. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 405-414.	0.5	45
95	Detection of early changes in the coronary artery microstructure after heart transplantation: A prospective optical coherence tomography study. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 486-495.	0.3	23
96	TCT-347 Culprit Lesion Types and Vascular Healing in Patients with ST-segment Elevation Myocardial Infarction after Primary Percutaneous Intervention. <i>Journal of the American College of Cardiology</i> , 2018, 72, B141.	1.2	0
97	TCT-792 Everolimus-eluting versus biolimus-eluting stent implantation in unselected patients with and without diabetes: a SORT OUT VIII substudy. <i>Journal of the American College of Cardiology</i> , 2018, 72, B315.	1.2	0
98	Should the Presence or Extent of Coronary Artery Disease be Quantified in the CHA2DS2-VASc Score in Atrial Fibrillation? A Report from the Western Denmark Heart Registry. <i>Thrombosis and Haemostasis</i> , 2018, 118, 2162-2170.	1.8	32
99	Coronary stent implantation and adverse cardiac events after surgery. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13030.	1.7	3
100	Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1437-1449.	1.1	111
101	Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent with the sirolimus-eluting Orsiro stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X trial. <i>American Heart Journal</i> , 2018, 202, 49-53.	1.2	12
102	CAD Is an Independent Risk Factor for Stroke Among Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2540-2542.	1.2	18
103	Two-year outcome after biodegradable polymer sirolimus- and biolimus-eluting coronary stents (from) Tj ETQq1 1 0,784314 rgBT /Over	1.4	17
104	Editor's Choice-Acute versus subacute angiography in patients with non-ST-elevation myocardial infarction â€” the NONSTEMI trial phase I. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 490-499.	0.4	14
105	Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 255-264.	1.1	38
106	Effect of Ischemic Postconditioning During Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 490.	3.0	105
107	Patients With Diabetes Without Significant Angiographic Coronary Artery Disease Have the Same Risk of Myocardial Infarction as Patients Without Diabetes in a Real-World Population Receiving Appropriate Prophylactic Treatment. <i>Diabetes Care</i> , 2017, 40, 1103-1110.	4.3	37
108	Severe Mental Illness and Clinical Outcome After Primary Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2017, 120, 550-555.	0.7	21

#	ARTICLE	IF	CITATIONS
109	Layered Fibrotic Plaques Are the Predominant Component in Cardiac Allograft Vasculopathy. JACC: Cardiovascular Imaging, 2017, 10, 773-784.	2.3	55
110	Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. New England Journal of Medicine, 2017, 376, 1813-1823.	13.9	740
111	The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis). JACC: Cardiovascular Interventions, 2017, 10, 2029-2037.	1.1	43
112	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. New England Journal of Medicine, 2017, 377, 1513-1524.	13.9	1,099
113	Perioperative myocardial infarction: in the twilight zone between surgery and cardiology. European Heart Journal, 2017, 38, 2418-2420.	1.0	2
114	Coronary artery disease and risk of adverse cardiac events and stroke. European Journal of Clinical Investigation, 2017, 47, 819-828.	1.7	23
115	Heart Failure and Ischemic Heart Disease in Patients With Rheumatoid Arthritis. Journal of the American College of Cardiology, 2017, 70, 3069-3071.	1.2	8
116	Nonculprit Stenosis Evaluation Using Instantaneous Wave-Free Ratio in Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2017, 10, 2528-2535.	1.1	55
117	Myocardial infarction with non-obstructive thrombus validated by optical coherence tomography. Scandinavian Cardiovascular Journal, 2017, 51, 61-68.	0.4	5
118	Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents. Thrombosis and Haemostasis, 2017, 117, 1989-1999.	1.8	26
119	Final five-year outcomes after implantation of biodegradable polymer-coated biolimus-eluting stents versus durable polymer-coated sirolimus-eluting stents. EuroIntervention, 2017, 13, 1336-1344.	1.4	11
120	EXCEL and NOBLE: stents or surgery for left main stem stenosis?. EuroIntervention, 2017, 13, e604-e608.	1.4	2
121	Dual anti-platelet therapy after coronary drug-eluting stent implantation and surgery-associated major adverse events. Thrombosis and Haemostasis, 2016, 116, 172-180.	1.8	15
122	Evaluation of algorithms for registry-based detection of acute myocardial infarction following percutaneous coronary intervention. Clinical Epidemiology, 2016, Volume 8, 415-423.	1.5	30
123	ST Elevation Infarction after Heart Transplantation Induced by Coronary Spasms and Mural Thrombus Detected by Optical Coherence Tomography. Case Reports in Transplantation, 2016, 2016, 1-4.	0.1	4
124	Risk Associated With Surgery Within 12 Months After Coronary Drug-Eluting Stent Implantation. Journal of the American College of Cardiology, 2016, 68, 2622-2632.	1.2	89
125	TCT-433 Feasibility, self-correcting properties and one-month results after implantation of a novolimus eluting bioresorbable stent in coronary bifurcations. The BIFSORB pilot study. Journal of the American College of Cardiology, 2016, 68, B174-B175.	1.2	2
126	TCT-318 Ten-year All-cause Mortality after Simple versus Complex Stenting of Coronary Artery Bifurcation Lesions in the Randomized Nordic Bifurcation Study. Journal of the American College of Cardiology, 2016, 68, B131-B132.	1.2	1

#	ARTICLE	IF	CITATIONS
127	TCT-261 Impact of Diabetes on Clinical Outcomes after Revascularization with Sirolimus-eluting and Biolimus-Eluting Stents with biodegradable polymer. From the SORT OUT VII Trial. Journal of the American College of Cardiology, 2016, 68, B106.	1.2	0
128	TCT-321 Definite and probable stent thrombosis after revascularization with drug-eluting stents with a biodegradable polymer. From the randomized SORT OUT VII Trial. Journal of the American College of Cardiology, 2016, 68, B133.	1.2	0
129	Gastrosocopy-related adverse cardiac events and bleeding complications among patients treated with coronary stents and dual antiplatelet therapy. Endoscopy International Open, 2016, 04, E527-E533.	0.9	5
130	Coronary bifurcation lesions treated with simple or complex stenting: 5-year survival from patient-level pooled analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. European Heart Journal, 2016, 37, 1923-1928.	1.0	103
131	Impact of thrombus aspiration during ST-Elevation Myocardial Infarction: a six month composite endpoint and risk of stroke analyses of the TASTE trial. BMC Cardiovascular Disorders, 2016, 16, 62.	0.7	10
132	The EBC TWO Study (European Bifurcation Coronary TWO). Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	102
133	Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	104
134	Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis. Scientific Reports, 2016, 6, 33054.	1.6	14
135	Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet, The, 2016, 388, 2743-2752.	6.3	620
136	Staged re-evaluation of non-culprit lesions in ST segment elevation myocardial infarction: a retrospective study. Open Heart, 2016, 3, e000427.	0.9	6
137	Danish study of Non-Invasive testing in Coronary Artery Disease (Dan-NICAD): study protocol for a randomised controlled trial. Trials, 2016, 17, 262.	0.7	43
138	Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel ADESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions. JACC: Cardiovascular Interventions, 2016, 9, 565-574.	1.1	91
139	Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents. Journal of the American College of Cardiology, 2016, 67, 751-762.	1.2	116
140	A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the diabedES IV randomized angiography trial). Catheterization and Cardiovascular Interventions, 2015, 86, 1161-1167.	0.7	13
141	Regional systems-of-care for primary percutaneous coronary intervention in ST-elevation myocardial infarction. Coronary Artery Disease, 2015, 26, 713-722.	0.3	11
142	Coronary stents and non-cardiac surgery: to bridge or not to bridge?. Thrombosis and Haemostasis, 2015, 114, 211-213.	1.8	0
143	Randomized comparison of a sirolimus-eluting Orsiro stent with a biolimus-eluting Nobori stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for Randomized Trials with Clinical Outcome VII trial. American Heart Journal, 2015, 170, 210-215.	1.2	17
144	Reply. Journal of the American College of Cardiology, 2015, 66, 2266-2267.	1.2	0

#	ARTICLE	IF	CITATIONS
145	ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. <i>European Heart Journal</i> , 2015, 36, 1252-1263.	1.0	366
146	Long-Term Outcome of Sirolimus-Eluting and Zotarolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus (A Danish Organization for Randomized Trials on) <i>Tj ETQq0 0 0 rgBT /0verlock 10 Tf 50 69</i>	0.7	16
147	Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial. <i>Lancet, The</i> , 2015, 385, 1527-1535.	6.3	107
148	Co-registration of optical coherence tomography and X-ray angiography in percutaneous coronary intervention. The Does Optical Coherence Tomography Optimize Revascularization (DOCTOR) fusion study. <i>International Journal of Cardiology</i> , 2015, 182, 272-278.	0.8	41
149	Safety of therapeutic hypothermia combined with primary percutaneous coronary intervention after out-of-hospital cardiac arrest. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 60-63.	0.4	10
150	Impact of Side Branch Modeling on Computation of Endothelial Shear Stress in Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 125-135.	1.2	75
151	Influence of multivessel disease with or without additional revascularization on mortality in patients with ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2015, 170, 70-78.	1.2	21
152	Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1619-1629.	1.2	401
153	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1089-1090.	1.2	3
154	Deliver the drug and be resorbed: evidence from ABSORB Japan. <i>European Heart Journal</i> , 2015, 36, 3343-3345.	1.0	4
155	Pain and discomfort in closure of femoral access coronary angiography. The CLOSuredEvices Used in everyday Practice (CLOSE-UP) pain sub study. <i>European Journal of Cardiovascular Nursing</i> , 2014, 13, 221-226.	0.4	12
156	Clinical use of optical coherence tomography to identify angiographic silent stent thrombosis. <i>Scandinavian Cardiovascular Journal</i> , 2014, 48, 156-160.	0.4	3
157	Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial. <i>Lancet, The</i> , 2014, 383, 2047-2056.	6.3	96
158	Rationale and design of The Intracoronary Stenting and Antithrombotic Regimenâ€”Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oral anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study. <i>American Heart Journal</i> , 2014, 167, 459-465.e1.	1.2	19
159	Intimal hyperplasia and vascular remodeling after everolimusâ€eluting and sirolimusâ€eluting stent implantation in diabetic patients: The randomized diabetes and drugâ€eluting stent (DiabeDES) IV intravascular ultrasound trial. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 864-872.	0.7	8
160	Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 100.	0.7	27
161	TCT-595 Early Healing After Treatment Of Coronary Lesions By Everolimus, Or Biolimus Eluting Bioresorbable Polymer Stents. One-month Results In The SORT-OUT VIII Optical Coherence Tomography Study. <i>Journal of the American College of Cardiology</i> , 2014, 64, B174.	1.2	0
162	Outcomes 1 Year after Thrombus Aspiration for Myocardial Infarction. <i>New England Journal of Medicine</i> , 2014, 371, 1111-1120.	13.9	337

#	ARTICLE	IF	CITATIONS
163	TCT-641 Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients With Coronary Artery Disease: SORT OUT IV 5-year. <i>Journal of the American College of Cardiology</i> , 2014, 64, B186-B187.	1.2	1
164	Three-Year Outcomes After Revascularization With Everolimus- and Sirolimus-Eluting Stents From the SORT OUT IV Trial. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 840-848.	1.1	28
165	Long-term outcome following percutaneous coronary intervention with drug-eluting stents compared with bare-metal stents in saphenous vein graft lesions: From Western Denmark heart registry. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 1035-1042.	0.7	11
166	Randomised comparison of manual compression and FemoSeal [®] vascular closure device for closure after femoral artery access coronary angiography: the CLOSure dEVICES Used in everyday Practice (CLOSE-UP) study. <i>EuroIntervention</i> , 2014, 10, 183-190.	1.4	54
167	Outcomes after revascularisation with everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes and stable angina pectoris: a substudy of the SORT OUT IV trial. <i>EuroIntervention</i> , 2014, 10, 212-223.	1.4	8
168	Long-Term Results After Simple Versus Complex Stenting of Coronary Artery Bifurcation Lesions. <i>Journal of the American College of Cardiology</i> , 2013, 62, 30-34.	1.2	168
169	Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction. <i>New England Journal of Medicine</i> , 2013, 369, 1587-1597.	13.9	943
170	TCT-598 Mechanisms of Incomplete Stent Apposition After Implantation of Drug-eluting Stents in patients with ST-segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 62, B181.	1.2	0
171	Clinical Outcome After Crush Versus Culotte Stenting of Coronary Artery Bifurcation Lesions. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1160-1165.	1.1	51
172	Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. <i>Lancet, The</i> , 2013, 381, 661-669.	6.3	173
173	Positive Predictive Value of Clinically Suspected ST-Segment Elevation Myocardial Infarction Using Angiographic Verification. <i>American Journal of Cardiology</i> , 2013, 112, 923-927.	0.7	7
174	Coronary Edema Demonstrated by Cardiovascular Magnetic Resonance in Patients With Peri-Stent Inflammation and Aneurysm Formation After Treatment by Drug-Eluting Stents. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 352-354.	1.3	5
175	Outcomes after primary percutaneous coronary intervention in octogenarians and nonagenarians with ST-segment elevation myocardial infarction: From the Western Denmark heart registry. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 912-919.	0.7	68
176	Incidence of definite stent thrombosis or in-stent restenosis after drug-eluting stent implantation for treatment of coronary in-stent restenosis: From Western Denmark heart registry. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 260-265.	0.7	13
177	Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention. <i>Circulation</i> , 2012, 125, 1246-1255.	1.6	149
178	Comparison of zotarolimus-eluting and sirolimus-eluting coronary stents: a study from the Western Denmark Heart Registry. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 84.	0.7	2
179	2-Year Patient-Related Versus Stent-Related Outcomes. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1140-1147.	1.2	42
180	TCT-297 Stent edge dissections detected by Optical Coherence Tomography, incidence, predictors and 12-month outcome. <i>Journal of the American College of Cardiology</i> , 2012, 60, B84.	1.2	1

#	ARTICLE	IF	CITATIONS
181	TCT-301 Feasibility and Results of Novel Side Branch Evaluation by Reconstructed 3-Dimensional Optical Coherence Tomography. Matched Analysis of Baseline and 12-month follow-up in Native, Jailed and Opened Side Branches. <i>Journal of the American College of Cardiology</i> , 2012, 60, B85-B86.	1.2	0
182	TCT-347 Clinical Outcome Of Biolimus-Eluting Versus Sirolimus-Eluting Coronary Stent Implantation In Patients With And Without Diabetes Mellitus: A SORT OUT V Substudy. <i>Journal of the American College of Cardiology</i> , 2012, 60, B98-B99.	1.2	0
183	TCT-531 Positive Predictive Value Of Clinically Suspected ST-Segment Elevation Myocardial Infarction Using Angiographic Verification. <i>Journal of the American College of Cardiology</i> , 2012, 60, B154.	1.2	0
184	3-Year Clinical Outcomes in the Randomized SORT OUT III Superiority Trial Comparing Zotarolimus- and Sirolimus-Eluting Coronary Stents. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 812-818.	1.1	43
185	Comparison of Outcomes in Patients With Versus Without Diabetes Mellitus After Revascularization With Everolimus- and Sirolimus-Eluting Stents (from the SORT OUT IV Trial). <i>American Journal of Cardiology</i> , 2012, 110, 1585-1591.	0.7	48
186	Influence of Diabetes Mellitus on Clinical Outcomes Following Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2012, 109, 629-635.	0.7	54
187	Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 161-170.	1.1	14
188	Use of clopidogrel and calcium channel blockers and risk of major adverse cardiovascular events. <i>European Journal of Clinical Investigation</i> , 2012, 42, 266-274.	1.7	14
189	Zotarolimus-eluting vs. sirolimus-eluting coronary stents in patients with and without acute coronary syndromes: a SORT OUT III substudy. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1047-1054.	1.7	10
190	Clinical outcomes after treatment of multiple lesions with zotarolimus-eluting versus sirolimus-eluting coronary stents (a SORT OUT III substudy). <i>BMC Cardiovascular Disorders</i> , 2012, 12, 18.	0.7	0
191	Side branch fractional flow reserve measurements after main vessel stenting: a Nordic-Baltic Bifurcation Study III substudy. <i>EuroIntervention</i> , 2012, 7, 1155-1161.	1.4	59
192	Culprit only or multivessel percutaneous coronary interventions in patients with ST-segment elevation myocardial infarction and multivessel disease. <i>EuroIntervention</i> , 2012, 8, 456-464.	1.4	37
193	The risk and prognostic impact of definite stent thrombosis or in-stent restenosis after coronary stent implantation. <i>EuroIntervention</i> , 2012, 8, 591-598.	1.4	17
194	COMMENTARY: Deliver the Drug and Disappear: Is the Bioabsorbable Magnesium Stent Growing Up or Still Shrinking?. <i>Journal of Endovascular Therapy</i> , 2011, 18, 416-417.	0.8	0
195	A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease. <i>American Heart Journal</i> , 2011, 162, 740-747.	1.2	24
196	Nonsteroidal Antiinflammatory Drug Use and Cardiovascular Risks After Coronary Stent Implantation. <i>Pharmacotherapy</i> , 2011, 31, 458-468.	1.2	8
197	System Delay and Timing of Intervention in Acute Myocardial Infarction (from the Danish Acute) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.7	52
198	Outcome of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus (a SORT OUT III Substudy). <i>American Journal of Cardiology</i> , 2011, 108, 1232-1237.	0.7	39

#	ARTICLE	IF	CITATIONS
199	Comparison of Outcomes of Patients \geq 80 Years of Age Having Percutaneous Coronary Intervention According to Presentation (Stable vs Unstable Angina Pectoris/Non-ST-Segment Elevation Myocardial Infarction). <i>Catheterization and Cardiovascular Interventions</i> , 2011, 78, 1395-1400.	0.7	14
200	Quantitative coronary analysis in the Nordic Bifurcation studies. <i>International Journal of Cardiovascular Imaging</i> , 2011, 27, 175-180.	0.7	15
201	The impact of acquisition angle differences on three-dimensional quantitative coronary angiography. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 78, 214-222.	0.7	20
202	Randomized Comparison of Final Kissing Balloon Dilatation Versus No Final Kissing Balloon Dilatation in Patients With Coronary Bifurcation Lesions Treated With Main Vessel Stenting. <i>Circulation</i> , 2011, 123, 79-86.	1.6	269
203	Late lumen loss and intima hyperplasia after sirolimus-eluting and zotarolimus-eluting stent implantation in diabetic patients: the diabetes and drug-eluting stent (DiabeDES III) angiography and intravascular ultrasound trial. <i>EuroIntervention</i> , 2011, 7, 323-331.	1.4	23
204	Use of three-dimensional optical coherence tomography to verify correct wire position in a jailed side branch after main vessel stent implantation. <i>EuroIntervention</i> , 2011, 7, 528-529.	1.4	9
205	Outcome in high risk patients with unprotected left main coronary artery stenosis treated with percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 101-108.	0.7	23
206	Zotarolimus-eluting versus sirolimus-eluting coronary stent implantation. <i>Interventional Cardiology</i> , 2010, 2, 807-812.	0.0	2
207	Time to Treatment and Three-Year Mortality After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: a DANish Trial in Acute Myocardial Infarction-2 (DANAMI-2) Substudy. <i>American Journal of Cardiology</i> , 2010, 105, 1528-1534.	0.7	45
208	Long-Term Outcomes After Percutaneous Coronary Intervention in Patients With and Without Diabetes Mellitus in Western Denmark. <i>American Journal of Cardiology</i> , 2010, 105, 1513-1519.	0.7	41
209	Existing data sources for clinical epidemiology: The Western Denmark Heart Registry. <i>Clinical Epidemiology</i> , 2010, 2, 137.	1.5	147
210	Primary Angioplasty Versus Fibrinolysis in Acute Myocardial Infarction. <i>Circulation</i> , 2010, 121, 1484-1491.	1.6	83
211	Response to Letter Regarding Article, "Primary Angioplasty Versus Fibrinolysis in Acute Myocardial Infarction: Long-Term Follow-Up in the Danish Acute Myocardial Infarction 2 Trial". <i>Circulation</i> , 2010, 122, .	1.6	0
212	System Delay and Mortality Among Patients With STEMI Treated With Primary Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 763.	3.8	519
213	Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. <i>Lancet</i> , 2010, 375, 1090-1099.	6.3	198
214	Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. <i>EuroIntervention</i> , 2010, 5, 898-905.	1.4	42
215	Randomized Comparison of Coronary Bifurcation Stenting With the Crush Versus the Culotte Technique Using Sirolimus Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 27-34.	1.4	156
216	Lack of cardioprotection from subcutaneously and preischemic administered Liraglutide in a closed chest porcine ischemia reperfusion model. <i>BMC Cardiovascular Disorders</i> , 2009, 9, 31.	0.7	65

#	ARTICLE	IF	CITATIONS
217	Comparison of the Sirolimus-Eluting Versus Paclitaxel-Eluting Coronary Stent in Patients With Diabetes Mellitus: The Diabetes and Drug-Eluting Stent (DiabeDES) Randomized Angiography Trial—A list of participating centers and investigators appears in the Appendix.. American Journal of Cardiology, 2009, 103, 345-349.	0.7	55
218	Serial Intravascular Ultrasound Analysis of Peri-Stent Remodeling and Proximal and Distal Edge Effects After Sirolimus-Eluting or Paclitaxel-Eluting Stent Implantation in Patients With Diabetes Mellitus. American Journal of Cardiology, 2009, 103, 1083-1088.	0.7	16
219	Timing, Causes, and Predictors of Death After Three Years' Follow-Up in the Danish Multicenter Randomized Study of Fibrinolysis Versus Primary Angioplasty in Acute Myocardial Infarction (DANAMI-2) Trial. American Journal of Cardiology, 2009, 104, 210-215.	0.7	18
220	2-Year Clinical Outcomes After Implantation of Sirolimus-Eluting, Paclitaxel-Eluting, and Bare-Metal Coronary Stents. Journal of the American College of Cardiology, 2009, 53, 658-664.	1.2	316
221	Effects of pentoxifylline on the vascular response to injury after angioplasty in rabbit iliac arteries. Basic Research in Cardiology, 2008, 103, 257-264.	2.5	10
222	Comparison of Intravascular Ultrasound and Angiographic Assessment of Coronary Reference Segment Size in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2008, 101, 590-595.	0.7	27
223	Intravascular Ultrasound Assessment of Expansion of the Sirolimus-Eluting (Cypher Select) and Paclitaxel-Eluting (Taxus Express-2) Stent in Patients With Diabetes Mellitus. American Journal of Cardiology, 2008, 102, 19-26.	0.7	14
224	Comparison of Stent Thrombosis, Myocardial Infarction, and Mortality Following Drug-Eluting Versus Bare-Metal Stent Coronary Intervention in Patients With Diabetes Mellitus. American Journal of Cardiology, 2008, 102, 165-172.	0.7	31
225	Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: The Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial. European Heart Journal, 2008, 29, 2733-2741.	1.0	39
226	Negative vascular remodelling after implantation of bioabsorbable magnesium alloy stents in porcine coronary arteries: a randomised comparison with bare-metal and sirolimus-eluting stents. Heart, 2008, 95, 241-246.	1.2	57
227	Clinical Outcome After Primary Percutaneous Coronary Intervention With Drug-Eluting and Bare Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2008, 1, 176-184.	1.4	30
228	The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI-2 trial): outcome after 3 years follow-up. European Heart Journal, 2007, 29, 1259-1266.	1.0	71
229	Intravascular ultrasound assessment of remodelling and reference segment plaque burden in type-2 diabetic patients. European Heart Journal, 2007, 28, 1759-1764.	1.0	42
230	Target lesion revascularisation in patients treated with a sirolimus-eluting or paclitaxel-eluting stent. Heart, 2007, 93, 694-697.	1.2	16
231	Intravascular ultrasound and angiographic assessment of reference segment size in type-2 diabetic patients. International Journal of Cardiology, 2007, 119, S27-S28.	0.8	0
232	Stent Thrombosis, Myocardial Infarction, and Death After Drug-Eluting and Bare-Metal Stent Coronary Interventions. Journal of the American College of Cardiology, 2007, 50, 463-470.	1.2	229
233	Acute haemodynamic effects of erythropoietin alone and in combination with dopamine in a porcine model. Clinical Physiology and Functional Imaging, 2006, 26, 283-287.	0.5	2
234	Effects of Levosimendan on Myocardial Infarct Size and Hemodynamics in a Closed-Chest Porcine Ischemia—Reperfusion Model. Cardiovascular Drugs and Therapy, 2006, 20, 335-342.	1.3	10

#	ARTICLE	IF	CITATIONS
235	Hypothermia during reperfusion does not reduce myocardial infarct size in pigs. Basic Research in Cardiology, 2006, 101, 61-68.	2.5	72
236	A phase of increased ST elevation during coronary occlusion following ischemic preconditioning. Basic Research in Cardiology, 2006, 101, 140-148.	2.5	4
237	Randomized Study on Simple Versus Complex Stenting of Coronary Artery Bifurcation Lesions. Circulation, 2006, 114, 1955-1961.	1.6	666
238	Routine Thrombectomy in Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction. Circulation, 2006, 114, 40-47.	1.6	242
239	Impact of drug eluting stents on target vessel revascularization. A report from the Western Denmark heart registry from 2000 to 2004. EuroIntervention, 2006, 1, 391-5.	1.4	1
240	Lack of acute cardioprotective effect from preischemic erythropoietin administration in a porcine coronary occlusion model. Clinical Physiology and Functional Imaging, 2005, 25, 305-310.	0.5	28
241	Lack of cardioprotection from metabolic support with glutamine or glutamate in a porcine coronary occlusion model. Scandinavian Cardiovascular Journal, 2005, 39, 115-120.	0.4	6
242	The natural history of collagen and α -actin expression after coronary angioplasty. Cardiovascular Pathology, 2004, 13, 260-267.	0.7	19
243	Myocardial perfusion imaging with ^{99m}Tc sestamibi early after reperfusion reliably reflects infarct size reduction by ischemic preconditioning in an experimental porcine model. Nuclear Medicine Communications, 2004, 25, 495-500.	0.5	12
244	Myocardial cooling for reperfusion injury protection achieved by organ specific hypothermic autologous perfusion. Scandinavian Cardiovascular Journal, 2003, 37, 297-303.	0.4	7
245	Adventitial Myofibroblasts Play no Major Role in Neointima Formation After Angioplasty. Scandinavian Cardiovascular Journal, 2003, 37, 34-42.	0.4	13